N
17.96
-0.24 (-1.32%)
| 前收盘价格 | 18.20 |
| 收盘价格 | 19.01 |
| 成交量 | 1,006,111 |
| 平均成交量 (3个月) | 896,650 |
| 市值 | 2,016,387,072 |
| 价格/销量 (P/S) | 40.12 |
| 股市价格/股市净资产 (P/B) | 3.46 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 营业利益率 (TTM) | -2,314.47% |
| 稀释每股收益 (EPS TTM) | -1.84 |
| 季度收入增长率 (YOY) | 112.60% |
| 总债务/股东权益 (D/E MRQ) | 0.05% |
| 流动比率 (MRQ) | 19.98 |
| 营业现金流 (OCF TTM) | -140.43 M |
| 杠杆自由现金流 (LFCF TTM) | -99.00 M |
| 资产报酬率 (ROA TTM) | -18.15% |
| 股东权益报酬率 (ROE TTM) | -31.51% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | NewAmsterdam Pharma Company N.V | 看跌 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.75 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.39% |
| 机构持股比例 | 111.32% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (Wells Fargo, 150.56%) | 购买 |
| 中 | 41.00 (128.29%) | |
| 低 | 27.00 (Goldman Sachs, 50.33%) | 保留 |
| 平均值 | 39.50 (119.93%) | |
| 总计 | 5 购买, 1 保留 | |
| 平均价格@调整类型 | 21.83 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 25 Aug 2025 | 45.00 (150.56%) | 购买 | 24.70 |
| RBC Capital | 07 Aug 2025 | 39.00 (117.15%) | 购买 | 22.96 |
| Goldman Sachs | 17 Jul 2025 | 27.00 (50.33%) | 保留 | 21.98 |
| Citigroup | 17 Jun 2025 | 42.00 (133.85%) | 购买 | 18.49 |
| Needham | 12 Jun 2025 | 40.00 (122.72%) | 购买 | 21.03 |
| Stifel | 10 Jun 2025 | 44.00 (144.99%) | 购买 | 21.84 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合